Abstract | PURPOSE OF REVIEW:
Myoclonus remains a challenging movement phenotype to characterize, evaluate, and treat. A systematic assessment of the temporal sequence, phenomenology, and distribution of movements can assist in the rational approach to diagnosis and management. RECENT FINDINGS: SUMMARY:
Myoclonus can be a prominent manifestation of a wide range of disorders. Electrophysiologic testing aids in distinguishing myoclonus from other mimics and classifying them according to cortical, subcortical, or spinal origin, which assists the choice of treatment. Despite the lack of randomized clinical trials, levetiracetam appears most effective in patients with cortical myoclonus, whereas clonazepam remains the only first-line therapeutic option in subcortical and spinal myoclonus.
|
Authors | Alberto J Espay, Robert Chen |
Journal | Continuum (Minneapolis, Minn.)
(Continuum (Minneap Minn))
Vol. 19
Issue 5 Movement Disorders
Pg. 1264-86
(Oct 2013)
ISSN: 1538-6899 [Electronic] United States |
PMID | 24092290
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anticonvulsants
(therapeutic use)
- Child
- Diagnosis, Differential
- Dystonic Disorders
(diagnosis)
- Epilepsies, Myoclonic
(diagnosis)
- Female
- Humans
- Male
- Myoclonus
(diagnosis, drug therapy, etiology)
- Neurodegenerative Diseases
(complications)
- Renal Insufficiency
(complications)
|